neonatal

L-Albizziin (2-Methoxyidazoxan monohydrochloride) 是高效的 alpha 2r 肾上腺素受体选择性拮抗剂，对 imidazoline 拮抗作用很小或没有。它对 (豚鼠) alpha 2D 肾上腺素受体 (pKd9.7) 的亲和力明显高于 (兔子) alpha 2A 肾上腺素受体 (pKd8.2)。

Temocapil 是一种酪氨酸激酶抑制剂。

CGP 35348 是 GABAB 受体的选择性拮抗剂 (EC50 = 34 μM)。 CGP 35348 可用于研究白化新生小鼠脑损伤后的神经肌肉协调和空间学习。

Temocapril hydrochloride (CS-622 HCl) 是血管紧张素转化酶 (ACE) 抑制剂。Temocapril HCl 能够用于充血性心力衰竭、急性心肌梗死、高血压、胰岛素抵抗和肾脏疾病的研究。

Enalaprilat (Enalapril acid) 是一种高效性的血管紧张素转换酶 (ACE) 抑制剂，，可增强心力衰竭患者对交感神经活动的动脉和心肺压力反射控制，可用于研究心血管疾病。

FUREGRELATE 是一种血栓素 A2 (TxA2) 合酶抑制剂，可减缓新生仔猪肺动脉高压的发展。

(R)-3,4-DCPG HCl 是一种强效和选择性的mGlu8a 受体激动剂，可激活新生大鼠脊髓初级传入终端上的代谢性谷氨酸受体。

Rocepafant (LAU8080) 是一种血小板活化因子(PAF)拮抗剂，可减轻新生大鼠缺氧缺血性脑损伤。Rocepafant 抑制肿瘤坏死因子-Afa 介导的小鼠 L929 肿瘤细胞的细胞毒性。

Oxodipine 是一种二氢吡啶型钙拮抗剂 ，抑制了KCl 诱导的兔主动脉收缩，降低了效力较低的大鼠心室试纸收缩的心脏力量。在大鼠培养的新生儿心室肌细胞中，Oxodipine 降低了L 型Ca 电流（I），IC 为0.24μM，对T 型Ca 电流（I）的IC 为0.41μM。Oxodipine 会使小鼠便秘和狗牙龈增生。

L-Pipecolic acid (L-Homoproline) 是赖氨酸的分解产物，它能在患有常染色体遗传性疾病的婴儿体液中积累，比如新生儿肾上腺机能障碍， Zellweger 综合征等。

Tridecanedioic acid (Brassilic acid) 是内源性代谢产物的一种。

Reverse T3 (3,3',5'-triiodo-L-thyronine) 是由甲状腺素原脱碘后产生的甲状腺激素。它可抑制由其它甲状腺激素类似物引起的新生大鼠心肌细胞中钠电流增加的作用。

Galactose是一种广泛存在于大多数活细胞中的单糖和己醛糖，主要通过SGLT1和GLUT2转运蛋白吸收进入血液循环，通过Leloir途径代谢。Galactose对猴肾CoS-1细胞中的Alglucerase具有抑制活性，是细胞糖缀合物的重要组成部分，在新生儿神经发育中具有重要作用。

BMS-470539 dihydrochloride 是一种具有选择性和高效性的黑皮质素 1 受体 (MC-1 R) 激动剂，具有抗炎活性。 BMS-470539 在新生儿缺氧缺血大鼠模型中通过 MC1R/cAMP/PKA/Nurr1 信号通路减轻氧化应激和神经元凋亡。

ZP3022是一种兼具glucagon-like peptide 1 receptor (GLP-1R)和cholecystokinin 2 (CCK2) receptor的激动剂。它在表达GLP-1R或CCK2 receptor的HEK293细胞中，选择性增加cAMP积累或ERK磷酸化，而在表达CCK1 receptor的HEK293细胞中，该作用较弱（人类受体的EC50分别为0.02, 10.3和>1,000 nM）。ZP3022（40 nM）在体外实验中促进大鼠新生β细胞的增殖，并在大鼠胰岛中以10和100 nM浓度应用时增强葡萄糖诱导的胰岛素分泌（GSIS），同时以40 nmol/kg剂量每日两次给药可减少大鼠体重。在db/db小鼠中，每日100 nmol/kg剂量的ZP3022增加β细胞和胰腺总体积，同时改善葡萄糖耐量。此外，它在db/db小鼠中降低食物摄入量，但不影响体重。

ADR-925 是右雷佐生的一种活性螯合铁代谢物，具有使新生大鼠心肌细胞免受阿霉素诱导的损伤的能力。

Biliatresone 是一种从球藻 Dysphania glomulifera 和 D. littoralis 中分离出来的环境毒素，诱导 C57BL/6J 新生儿胆管病，诱导谷胱甘肽 （GSH） 水平降低，诱导 SOX17 胆管细胞水平显着降低，诱导小鼠肝外胆管细胞损伤和纤维化。

Nitisinone-13C6is intended for use as an internal standard for the quantification of nitisinone by GC- or LC-MS. Nitisinone is an inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD), which converts 4-hydroxyphenylpyruvate (HPPA) to homogentisate in the tyrosine catabolic pathway.1Nitisinone increases urinary levels of HPPA and 4-hydroxyphenyllactate (HPLA) in rats when administered at a dose of 10 mg kg. Nitisinone (3 mg kg) prevents the neonatal lethality of fumarylacetoacetate hydrolase (FAH) deficiency in mice when administered to pregnant dams.2It exhibits hepatoprotective effects inFAH- -mice, such as prevention of increases in plasma levels of aspartate serine aminotransferase (AST) and conjugated bilirubin, when administration is continued following birth at a dose of 1 mg kg. Nitisinone (100 μg) decreases urinary excretion of homogentisate and increases urinary excretion of HPPA, HPLA, and 4-hydroxyphenylacetate in a mouse model of alkaptonuria induced by ethylnitrosourea.3Formulations containing nitisinone have been used in the treatment of hereditary tyrosinemia type 1 (HT-1). 1.Ellis, M.K., Whitfield, A.C., Gowans, L.A., et al.Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dioneToxicol. Appl. Pharmacol.133(1)12-19(1995) 2.Grompe, M., Lindstedt, S., al-Dhalimy, M., et al.Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type INat. Genet.10(4)453-460(1995) 3.Suzuki, Y., Oda, K., Yoshikawa, Y., et al.A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuriaJ. Hum. Genet.44(2)79-84(1999)

17R(18S)-EpETE is an oxylipin and a cytochrome P450 metabolite of eicosapentaenoic acid .1,217R(18S)-EpETE is an activator of large-conductance calcium-activated potassium (BKCa) channels, increasing the potassium current amplitude by 15-fold in isolated rat cerebral artery vascular smooth muscle cells (VSMCs) at +60 mV when used at a concentration of 50 nM.2It has negative chronotropic effects in isolated neonatal rat cardiomyocytes (NRCMs; EC50= ~1-2 nM) and prevents calcium-induced increases in the spontaneous beating of NRCMs.3,4 1.Schwarz, D., Kisselev, P., Ericksen, S.S., et al.Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: Highly steroselective formation of 17(R), 18(S)-epoxyeicosatetraenoic acidBiochem. Pharmacol.67(8)1445-1457(2004) 2.Lauterbach, B., Barbosa-Sicard, E., Wang, M.H., et al.Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activatorsHypertension39(2 Pt. 2)609-613(2002) 3.Falck, J.R., Wallukat, G., Puli, N., et al.17(R),18(S)-Epoxyeicosatetraenoic acid, a potent eicosapentaenoic acid (EPA) derived regulator of cardiomyocyte contraction: Structure-activity relationships and stable analoguesJ. Med. Chem.54(12)4109-4118(2011) 4.Arnold, C., Markovic, M., Blossey, K., et al.Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of omega-3 fatty acidsJ. Biol. Chem.285(43)32720-32733(2010)

19R(20S)-EpDPA is an oxylipin and a metabolite of docosahexaenoic acid .1,2It is formed from DHA by various cytochrome P450 (CYP) isoforms in a stereoselective manner.219R(20S)-EpDPA (30 nM) prevents calcium-induced increases in the spontaneous beating of isolated neonatal rat cardiomyocytes (NRCMs).3 1.Cinelli, M.A., Yang, J., Scharmen, A., et al.Enzymatic synthesis and chemical inversion provide both enantiomers of bioactive epoxydocosapentaenoic acidsJ. Lipid Res.59(11)2237-2252(2018) 2.Lucas, D., Goulitquer, S., Marienhagen, J., et al.Stereoselective epoxidation of the last double bond of polyunsaturated fatty acids by human cytochromes P450J. Lipid Res.51(5)1125-1133(2010) 3.Burke, J.E., and Dennis, E.A.Phospholipase A2 structure/function, mechanism, and signalingJ. Lipid Res.50(Suppl)S237-S242(2009)

Burnettramic acid A is a fungal metabolite originally isolated fromA. burnettiithat has diverse biological activities.1It is active againstB. subtilis,S. aureus,C. albicans, andS. cerevisiae(IC50s = 2.3, 5.9, 0.5, and 0.2 μg ml, respectively). Burnettramic acid A is cytotoxic to NS-1 murine myeloma cells but not neonatal foreskin fibroblasts (IC50s = 13.8 and >100 μg ml, respectively). 1.Li, H., Gilchrist, C.L.M., Lacey, H.J., et al.Discovery and heterologous biosynthesis of the burnettramic acids: Rare PKS-NRPS-derived bolaamphiphilic pyrrolizidinediones from an Australian fungus, Aspergillus burnettiiOrg. Lett.21(5)1287-1291(2019)

Burnettramic acid A aglycone is a fungal metabolite and an aglycone form of burnettramic acid A originally isolated fromA. burnettiithat has anticancer activity.1It is cytotoxic to NS-1 murine myeloma cells but not neonatal foreskin fibroblasts (IC50s = 8.4 and >100 μg ml, respectively). 1.Li, H., Gilchrist, C.L.M., Lacey, H.J., et al.Discovery and heterologous biosynthesis of the burnettramic acids: Rare PKS-NRPS-derived bolaamphiphilic pyrrolizidinediones from an Australian fungus, Aspergillus burnettiiOrg. Lett.21(5)1287-1291(2019)

O-Desmethyl-N-deschlorobenzoyl indomethacin is a metabolite of the non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor indomethacin .1It is formed from indomethacin in isolated rabbit hepatocytes. O-Desmethyl-N-deschlorobenzoyl indomethacin (600 μM) decreases the viability of HL-60 leukemia cells when cultured with glucose oxidase.2It has also been used in the synthesis of prostaglandin D2receptor antagonists.3 1.Evans, M.A., Papazafiratou, C., Bhat, R., et al.Indomethacin metabolism in isolated neonatal and fetal rabbit hepatocytesPediatr. Res.15(11)1406-1410(1981) 2.Morgan, A.G.M., Babu, D., Michail, K., et al.An evaluation of myeloperoxidase-mediated bio-activation of NSAIDs in promyelocytic leukemia (HL-60) cells for potential cytotoxic selectivityToxicol. Lett.28048-56(2017) 3.Torisu, K., Kobayashi, K., Iwahashi, M., et al.Discovery of new chemical leads for prostaglandin D2 receptor antagonistsBioorg. Med. Chem. Lett.14(17)4557-4562(2004)

5-hydroxy Indomethacin is a metabolite of indomethacin .1It is formed from indomethacin in rabbit hepatic microsomes. 1.Evans, M.A., Papazafiratou, C., Bhat, R., et al.Indomethacin metabolism in isolated neonatal and fetal rabbit hepatocytesPediatr. Res.15(11)1406-1410(1981)